Pharming Group (PHGUF) Downgraded by Zacks Investment Research to Hold

Pharming Group (OTCMKTS:PHGUF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday, March 10th.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

A number of other equities research analysts have also recently weighed in on PHGUF. ValuEngine cut Pharming Group from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Roth Capital reaffirmed a “buy” rating on shares of Pharming Group in a research note on Wednesday, March 7th.

Shares of Pharming Group stock opened at $1.46 on Friday. Pharming Group has a 1 year low of $0.31 and a 1 year high of $1.96. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.31 and a quick ratio of 0.99.

TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.

Leave a Reply